Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Best Pract Res Clin Haematol. 2009 Dec;22(4):517-21. doi: 10.1016/j.beha.2009.09.001.
Maintenance therapy is not part of current standard treatment for acute myeloid leukaemia (AML). However, in other leukaemias, maintenance therapy is used to prolong responses and increase the cure rate. While maintenance chemotherapy has not been shown to improve outcome in AML, several other maintenance strategies are currently being tested in this disease, including immunotherapy, demethylating agents and targeted therapies. While maintenance chemotherapy does not appear to have a role in AML curative therapy, the novel maintenance strategies currently being tested appear promising and warrant further study.
维持治疗不是当前急性髓系白血病（AML）标准治疗的一部分。然而，在其他白血病中，维持治疗用于延长缓解期并提高治愈率。虽然维持化疗并未显示能改善 AML 的结局，但目前正在该疾病中测试几种其他维持策略，包括免疫疗法、去甲基化剂和靶向治疗。虽然维持化疗似乎在 AML 的治愈治疗中没有作用，但目前正在测试的新型维持策略似乎很有前景，值得进一步研究。
